Proinflammatory progranulin antibodies in inflammatory bowel diseases

Digestive Diseases and Sciences

Volumn 59, Issue 8, 2014, Pages 1733-1742

  Thurner, Lorenz ^a   Stöger, Elisabeth ^a   Fadle, Natalie ^a   Klemm, Philipp ^a   Regitz, Evi ^a   Kemele, Maria ^a   Bette, Birgit ^a   Held, Gerhard ^a   Dauer, Marc ^b   Lammert, Frank ^a   Preuss, Klaus Dieter ^a   Zimmer, Vincent ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b St Elisabeth Klinik   (Germany)

Author keywords

Crohn's disease; Inhibitor of TNFR1 2; Neutralizing proinflammatory progranulin antibody; Progranulin; Ulcerative colitis

Indexed keywords

IMMUNOGLOBULIN CLASS; NEUTRALIZING ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROGRANULIN ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CROHN DISEASE; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HT 29 CELL LINE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; HEK293 CELLS; HT29 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; SACCHAROMYCES CEREVISIAE; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84905595194     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3089-3     Document Type: Article

References (37)

1. Thurner L, Preuss KD, Fadle N, Regitz E, Klemm P, Zaks M, Kemele M, Hasenfus A, Csernok E, Gross WL, Pasquali JL, Martin T, Bohle RM, Pfreundschuh M. Progranulin antibodies in autoimmune diseases. J Autoimmun. 2012;42:29-28.
2. Toh H, Chitramuthu BP, Bennett HP, Bateman A. Structure, function, and mechanism of progranulin; the brain and beyond. J Mol Neurosci. 2011;45:538-548.
3. Kessenbrock K, Frohlich L, Sixt M, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest . 2008;118:2438-2447. (Pubitemid 351949772)
4. Tang W, Lu Y, Tian QY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332:478-484.
5. Sfikakis PP, Tsokos GC. Towards the next generation of anti-TNF drugs. Clin Immunol. 2011;141:231-235.
6. Chen X, Chang J, Deng Q, et al. Progranulin does not bind tumor necrosis factor (TNF) receptors and is not a direct regulator of TNF-dependent signaling or bioactivity in immune or neuronal cells. J Neurosci. 2013;33:9202-9213.
7. Etemadi N, Webb A, Bankovacki A, Silke J, Nachbur U. Progranulin does not inhibit TNF and lymphotoxin-alpha signalling through TNF receptor 1. Immunol Cell Biol. 2013;91:661-664.
8. Jian J, Zhao S, Tian Q, Gonzalez-Gugel E, Mundra JJ, Uddin SM, Liu B, Richbourgh B, Brunetti R, Liu CJ. Progranulin directly binds to the CRD2 and CRD3 of TNFR extracellular domains. FEBS Lett. 2013;587:3428-3436.
9. Egashira Y, Suzuki Y, Azuma Y, et al. The growth factor progranulin attenuates neuronal injury induced by cerebral ischemia-reperfusion through the suppression of neutrophil recruitment. J Neuroinflamm. 2013;10:105.
10. Kawase R, Ohama T, Matsuyama A, Matsuwaki T, Okada T, Yamashita T, Yuasa-Kawase M, Nakaoka H, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Masuda D, Nakagawa-Toyama Y, Nishida M, Ohmoto Y, Nishihara M, Komuro I, Yamashita S. Deletion of progranulin exacerbates atherosclerosis in ApoE knockout mice. Cardiovasc Res. 2013;100:125-133.
11. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2012;72:1947-1955.
12. Thurner L, Zaks M, Preuss KD, et al. Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis. Arthritis Res Ther. 2013;15:R211.
13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5-36.
14. Held G, Wadle A, Dauth N, et al. MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing. Eur J Immunol . 2007;37:2008-2017. (Pubitemid 47065136)
15. Preuss KD, Pfreundschuh M, Fadle N, et al. Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A. Blood. 2011;118:3340-3346.
16. de Haard HJ, van NN, Reurs A, et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem. 1999;274:18218-18230.
17. Chapman PB, Lester TJ, Casper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942-1951. (Pubitemid 18010154)
18. Wang J, van DH, Scherer HU, Huizinga TW, Toes RE. Suppressor activity among CD4 +, CD25 ++ T cells is discriminated by membrane-bound tumor necrosis factor alpha. Arthritis Rheum . 2008;58:1609-1618. (Pubitemid 351847514)
19. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066-2078.
20. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380:1590-1605.
21. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713-1725.
22. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785. (Pubitemid 36666774)
23. Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367:725-734.
24. Daniel R, He Z, Carmichael KP, Halper J, Bateman A. Cellular localization of gene expression for progranulin. J Histochem Cytochem. 2000;48:999-1009. (Pubitemid 30421564)
25. El FD, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedus L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut. 2008;57:714-715. (Pubitemid 351579988)
26. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007;13:1365-1368. (Pubitemid 350206846)
27. Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut. 2011;60:1520-1526.
28. Olson TS, Bamias G, Naganuma M, et al. Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J Clin Invest. 2004;114:389-398. (Pubitemid 39071611)
29. Velazquez P, Wei B, Braun J. Surveillance B lymphocytes and mucosal immunoregulation. Springer Semin Immunopathol. 2005;26:453-462. (Pubitemid 40468896)
30. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 1988;297:1105-1106.
31. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113: 1296-1306. (Pubitemid 39069929)
32. Seibold F, Brandwein S, Simpson S, Terhorst C, Elson CO. pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol. 1998;18:153-160. (Pubitemid 28120182)
33. MacDermott RP, Nash GS, Auer IO, et al. Alterations in serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease. Gastroenterology. 1989;96:764-768. (Pubitemid 19057597)
34. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912-922. (Pubitemid 28217556)
35. Arias-Loste MT, Bonilla G, Moraleja I, Mahler M, Mieses MA, Castro B, Rivero M, Crespo J, Lopez-Hoyos M. Presence of Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies (Anti-PR3 ANCA) as Serologic Markers in Inflammatory Bowel Disease. Clin Rev Allergy Immunol. 2013;45:109-116.
36. Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM. Anti- Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci. 2007;52:33-39. (Pubitemid 46122044)
37. Biancone L, Monteleone G, Marasco R, Pallone F. Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives. Clin Exp Immunol. 1998;113:198-205. (Pubitemid 28352837)